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A B S T R A C T
Purpose
This phase III randomized trial (ClinicalTrials.gov identifier: NCT00337103) compared eribulin with
capecitabine in patients with locally advanced or metastatic breast cancer (MBC).
Patients and Methods
Women with MBC who had received prior anthracycline- and taxane-based therapy were randomly
assigned to receive eribulin or capecitabine as their first-, second-, or third-line chemotherapy
for advanced/metastatic disease. Stratification factors were human epidermal growth factor
receptor-2 (HER2) status and geographic region. Coprimary end points were overall survival (OS)
and progression-free survival (PFS).
Results
Median OS times for eribulin (n  554) and capecitabine (n  548) were 15.9 and 14.5 months,
respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P .056). Median PFS times for eribulin
and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P  .30).
Objective response rates were 11.0% for eribulin and 11.5% for capecitabine. Global health status
and overall quality-of-life scores over time were similar in the treatment arms. Both treatments had
manageable safety profiles consistent with their known adverse effects; most adverse events
were grade 1 or 2.
Conclusion
In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS
or PFS.
J Clin Oncol © 2015 American Society of Clinical Oncology. Creative Commons Attribution
Non-Commercial No Derivatives 3.0 License: https://creativecommons.org/licenses/by-nc-nd/3.0/us/
INTRODUCTION
Overall survival (OS) for women with metastatic
breast cancer (MBC) has improved over recent de-
cades. Long-term survival, however, remains
poor,1,2 highlighting the unmet need for therapy
that is effective, improves quality of life (QoL), and
prolongs survival.
Anthracycline- or taxane-based regimens are
commonly used in the treatment of breast cancer,
often in the (neo)adjuvant and first-line meta-
static settings.3 However, treatment decisions in
subsequent lines are increasingly difficult.4 There
is no single accepted standard of care after failure
of anthracycline and taxane therapy5; capecit-
abine is commonly used in the first-, second-, and
third-line settings forMBC. Capecitabine has also
been the control arm in several phase III trials in
MBC.6-9
Eribulin mesylate (International Nonpropri-
etary Name is eribulin) is a nontaxane microtubule
dynamics inhibitor belonging to the halichondrin
class of antineoplastic agents.10,11 It has a mecha-
nism of action distinct from other tubulin-
targeted agents, binding predominantly to a small
number of high-affinity sites on the growing plus
ends of microtubules.10-14 Such highly focused
end-binding may decrease the likelihood of ef-
fects from eribulin on normal physiologic micro-
tubule functions in nonmalignant cells.15,16 In
contrast to most other tubulin-targeted agents,
mitotic blockade with eribulin is irreversible, and
intermittent drug exposure leads to long-term
loss of cell viability.17
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Thefirst phase III trial of eribulin (EisaiMetastatic BreastCancer
Study Assessing Physician’s Choice Versus Eribulin [EMBRACE])
compared eribulin with treatment of physician’s choice (TPC) in
patients withMBCwho had received at least two prior chemotherapy
regimens for advanced disease but no more than five cytotoxic regi-
mens in total. In this trial, there was a significant improvement in OS
for eribulin compared with TPC; this was confirmed in the updated
analysis requested by European and US regulatory authorities. The
medianOSwas 13.2months for eribulin versus 10.5months for TPC
(hazard ratio [HR], 0.81; 95% CI, 0.67 to 0.96; nominal [analysis not
prespecified]P .01). Furthermore, eribulinhad amanageable safety
profile,with themost commonadverse events (AEs)being astheniaor
fatigue, and neutropenia.18,19
As a result, eribulin has been approved inmore than50 countries
asmonotherapy forpatientswithadvancedbreast cancerorMBCwho
have previously received at least two chemotherapeutic regimens for
advanced/metastatic disease, with prior therapy having included an
anthracycline and a taxane in the adjuvant ormetastatic setting.20We
report results from a second phase III study comparing eribulin with
capecitabine as first-, second-, or third-line therapy for advanced
breast cancer or MBC. Detailed QoL and pharmacokinetic/pharma-
codynamic results will be reported separately.
PATIENTS AND METHODS
Patients
Inclusion criteria included: female sex; age 18 years; histologically or
cytologically confirmed breast cancer; up to three prior chemotherapy regi-
mens and up to two prior chemotherapy regimens for advanced and/or met-
astatic disease; prior therapy with an anthracycline and a taxane; resolution of
all chemotherapy-or radiation-related toxicities tograde1 (except for stable
sensory neuropathy grade 2 and alopecia); Eastern Cooperative Oncology
Group performance status of 0 to 2; and adequate renal, bone marrow, and
liver function. Measurable or nonmeasurable disease was allowed. Exclusion
criteria included prior capecitabine treatment and radiation therapy encom-
passing more than 30% of marrow. Patients with human epidermal growth
factor receptor 2 (HER2)–positive disease couldhave receivedHER2-targeted
therapy before or after study treatment but not while on study treatment.
Eligible for random assignment
(N = 1,102)
Randomly assigned
(N = 1,102)
Assigned to eribulin
(n = 554)
Assigned to capecitabine
(n = 548)
Received eribulin
(n = 544)
Received capecitabine
(n = 546)
Receiving eribulin at data cutoff (n = 5)
At data cutoff
)%61 ;78 = n( evilA  
)%18 ;644 = n( deid daH  
  Withdrew consent (n = 12; 2%)
  Lost to follow-up (n = 9; 2%)
Receiving capecitabine at data cutoff (n = 5)
At data cutoff
)%21 ;56 = n( evilA  
)%48 ;954 = n( deid daH  
  Withdrew consent (n = 9; 2%)
  Lost to follow-up (n = 15; 3%)
Intent-to-treat population (n = 554)
Per-protocol population (n = 521)
Safety population (n = 544)
Intent-to-treat population (n = 548)
Per-protocol population (n = 507)
Safety population (n = 546)
Not treated (n = 10)
  Entry criteria not met (n = 4)
  Other reasons (n = 1)
  Patient’s decision (n = 2)
  Withdrew consent (n = 3)
Not treated (n = 2)
  Entry criteria not met (n = 1)
  Withdrew consent (n = 1)
Discontinued study (n = 549)
  Progressive disease (RECIST) (n = 409)
  Adverse events (n = 45)
  Patient's decision (n = 34)
  Clinical progression (n = 27)
  Physician’s decision (n = 15)
  Withdrew consent (n = 8)
)1 = n( deiD  
  Other reasons (n = 10)
Discontinued study (n = 543)
  Progressive disease (RECIST) (n = 405)
  Adverse events (n = 59)
  Patient's decision (n = 27)
  Clinical progression (n = 24)
  Physician’s decision (n = 14)
  Withdrew consent (n = 5)
  Other reasons (n = 9)
Fig 1. CONSORT diagram.
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All patients provided written informed consent. Approval was ob-
tained from independent ethics committees and regulatory authorities in
participating countries. The study was conducted in accordance with the
World Medical Association Declaration of Helsinki, guidelines of the
International Conference for Harmonisation/Good Clinical Practice, and
local ethical and legal requirements.
Study Design
This phase III, open-label, parallel, two-arm,multicenter trial (studyNo.
E7389-G000-301; ClinicalTrials.gov identifier: NCT00337103) stratified pa-
tients by geographic region (Latin America, Western Europe/Australia, East-
ern Europe, North America, Asia, or South Africa) and the HER2 status of
their cancer (positive, negative, or unknown). Patients were randomly as-
signed (1:1) using a central interactive voice-response system to receive eribu-
lin mesylate 1.4 mg/m2 (equivalent to eribulin 1.23 mg/m2 [expressed as free
base]) intravenously over 2 to 5 minutes on days 1 and 8, or capecitabine
1.25 g/m2 orally twice per day on days 1 to 14, both in 21-day cycles. Patients
received study treatment until disease progression, unacceptable toxicity, or
patient/investigator request to discontinue. Grade 3 and 4 toxicities and
certain grade 2 toxicities for capecitabine were managed by treatment inter-
ruption and/or dose reduction and symptomatic treatment. Use of colony-
stimulating factors and erythropoietin was allowed according to American
Society of Clinical Oncology guidelines or local practice.
Study Objectives
Coprimary end points, as used in other clinical trials,21 were OS and
progression-free survival (PFS). Secondary end points included objective re-
sponse rate (ORR); duration of response; 1-, 2-, and 3-year survival; safety;
QoL; and population pharmacokinetic/pharmacodynamic relationships.
Study Assessments
OS was measured from date of random assignment until date of death
from any cause or last date known alive/data cutoff (censored). PFS was
measured from date of random assignment to date of recorded disease pro-
gression or death from any cause.
Tumor response was determined according to RECIST (version 1.0),
censored at last tumor assessment before subsequent anticancer therapy or
before two ormoremissed scheduled tumor assessments,22 and confirmed by
a second assessment at least 4 weeks after first observation of response. An
Table 1. Patient Demographic and Baseline Clinical Characteristics
(intent-to-treat population)
Characteristic
Eribulin
(n  554)
Capecitabine
(n  548)
No. of
Patients %
No. of
Patients %
Age, years
Median 54.0 53.0
Range 24-80 26-80
Race
White 496 89.5 495 90.3
Asian/Pacific Islander 18 3.2 18 3.3
Black or African American 15 2.7 16 2.9
Other 25 4.5 19 3.5
Geographic region
Eastern Europe 307 55.4 305 55.7
Latin America 105 19.0 104 19.0
Western Europe 80 14.4 77 14.1
North America 44 7.9 43 7.8
Asia 13 2.3 12 2.2
South Africa 5 0.9 7 1.3
ECOG performance status
0 250 45.1 230 42.0
1 293 52.9 301 54.9
2 11 2.0 16 2.9
3 0 0 1 0.2
No. of prior chemotherapy regimens
0 1 0.2 0 0
1 147 26.5 153 27.9
2 319 57.6 314 57.3
3 84 15.2 78 14.2
4 3 0.5 2 0.4
5 0 0 1 0.2
No. of prior chemotherapy regimens
for advanced disease
0 116 20.9 104 19.0
1 280 50.5 293 53.5
2 154 27.8 146 26.6
 2 4 0.7 5 0.9
Refractory to treatment with:
Taxane 250 45.1 260 47.4
Anthracycline 134 24.2 139 25.4
Taxane and anthracycline 91 16.4 103 18.8
HER2 status
Positive 86 15.5 83 15.1
Negative 375 67.7 380 69.3
Not done 93 16.8 85 15.5
ER status
Positive 259 46.8 278 50.7
Negative 233 42.1 216 39.4
Not done 62 11.2 54 9.9
PgR status
Positive 227 41.0 234 42.7
Negative 262 47.3 248 45.3
Not done 65 11.7 66 12.0
Triple (HER2/ER/PgR) negative 150 27.1 134 24.5
Most common metastatic sites†
Bone 299 54.0 308 56.2
Lung 279 50.4 280 51.1
Lymph nodes 268 48.4 274 50.0
Liver 247 44.6 271 49.5
(continued in next column)
Table 1. Patient Demographic and Baseline Clinical Characteristics
(intent-to-treat population) (continued)
Characteristic
Eribulin
(n  554)
Capecitabine
(n  548)
No. of
Patients %
No. of
Patients %
No. of organs involved
1 113 20.4 92 16.8
2 174 31.4 177 32.3
3 153 27.6 149 27.2
 4 114 20.6 129 23.5
Missing 0 0 1 0.2
Site of disease‡
Visceral 467 84.3 483 88.1
Nonvisceral only 81 14.6 61 11.1
Missing 6 1.1 4 0.7
Abbreviations: ECOG, Eastern Cooperative Oncology Group; ER, estrogen
receptor; HER2, human epidermal growth factor receptor 2; PgR, progester-
one receptor.
Refractory was defined as progression within 60 days after taking the
last dose.
†Reported by at least 20% of the total population.
‡Visceral/nonvisceral was determined by independent assessment.
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independent radiology review was performed; in a protocol amendment re-
questedby theUSFoodandDrugAdministration, abone scanwas required to
confirm tumor response. Duration of response was defined as the time from
first documented complete or partial responseuntil disease progression, death
from any cause, or censoring at date of last tumor assessment. AEs were
assessed according to the National Cancer Institute Common Terminology
Criteria for Adverse Events (version 3).
QoL Analyses
QoL was assessed using the European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire C30 (version 3.0) and
breastmoduleQuality of Life Questionnaire BR23 (version 1.0) at baseline, at
6 weeks, and at 3, 6, 12, 18, and 24 months or until disease progression or
initiation of other antitumor treatment. The principal prespecified outcome
was overall QoL, expressed as change from baseline in Global Health Status
(GHS)/QoLmeasured on a 0 (worst) to 100 (best) scale.
Statistical Analyses
Because there were coprimary end points, the total type I error was split,
0.04 forOS and0.01 for PFS. Sample sizewas basedon a superiority test ofOS;
when 905 events (deaths) were observed, the two-sided log-rank test had 90%
power to detect a 3-month increase in median survival over a 12-month
median survival for capecitabine (HR, 0.80). Planned enrollment was 1,100
patients with a maximum of 55 patients per study site.
Primary efficacy analysis used the intent-to-treat population comprising
all randomlyassignedpatients.The safetypopulation includedallpatientswho
received at least one dose of treatment. Tumor assessments were obtained
from an independent radiology review (primary analysis) and an investigator
radiology review (secondary analysis).
The coprimary end points, OS and PFS, were compared between treat-
ment groups using two-sided, stratified (geographic region andHER2 status)
log-rank tests. InterimplannedOS analyses were performed after 453 and 603
deaths. Tomaintain an overall level of 0.04, spending for sequential analyses
of OS was based on Lan-DeMets implementation of the O’Brien-Fleming
spending function23; the nominal significance levels of the first and second
interim analyses and final analysis were P .002, P .0081, and P .0372,
respectively. The study would be defined as positive if, at final analysis,
either OS with eribulin was statistically significantly better (P  .0372)
versus capecitabine or PFSwith eribulinwas statistically significantly better
(P  .01) versus capecitabine, and the HR for OS (eribulin/capecitabine)
was less than 1. ORRs were compared between treatment groups using
Fisher’s exact test. As prespecified in the statistical analyses plan, explor-
atory analyses of OS and PFS by the stratification factors of HER2 status
and geographic region were also performed.
For the principal QoL outcome, longitudinal analyses were carried out
using linear mixed model and pattern-mixture model techniques. An inde-
pendent data monitoring committee reviewed safety and efficacy data from
interim analyses. The sponsor (Eisai, Woodcliff Lake, NJ) collected and ana-
lyzed all datawith the exceptionof theQoLanalyses,whichwere conductedby
Clinical Outcomes Solutions (Evergreen, CO).
RESULTS
Patients
From September 2006 to September 2009, 1,102 patients were
randomly assigned, 554 to eribulin and 548 to capecitabine (Fig 1).
Baseline patient demographics and disease characteristics were gener-
ally well balanced (Table 1); there were small differences in the
percentagesofpatientswhohadestrogenreceptor–positive and triple-
negative disease (46.8% v 50.7%, and 27.1% v 24.5% for eribulin and
capecitabine, respectively). Overall, 68.5% of patients had HER2-
negative disease. Twenty percent, 52.0%, and 27.2% of patients re-
ceived study therapy as first-line, second-line, and third-line
treatment, respectively, for advanced disease.
Efficacy
Median OS was 15.9 months (95% CI, 15.2 to 17.6 months) for
eribulin compared with 14.5 months (95% CI, 13.1 to 16.0 months)
for capecitabine (Fig 2A), resulting in an HR of 0.88 (95%CI, 0.77 to
1.00; P  .056). Median PFS was 4.1 months (95% CI, 3.5 to 4.3
months) for eribulin and 4.2months (95%CI, 3.9 to 4.8months) for
capecitabine (HR, 1.08; 95% CI, 0.93 to 1.25; P  .30; Fig 2B). By
investigator review, median PFS times were 4.2 months (95% CI, 3.9
to 4.3 months) and 4.1 months (95% CI, 3.7 to 4.5 months) for
eribulinandcapecitabine, respectively (HR,0.98; 95%CI, 0.86 to1.11;
P .74).
ORRs by independent review were 11.0% (95% CI, 8.5% to
13.9%) and 11.5% (95%CI, 8.9% to 14.5%; P .85) for eribulin and
capecitabine, respectively (Table 2).ORRs by investigator reviewwere
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Eribulin 446/554 15.9 15.2 to 17.6
Capecitabine 459/548 14.5 13.1 to 16.0
HR, 0.88; 95% CI, 0.77 to 1.00
P = .056
No. at risk
Eribulin 554 505 423 349 268 214 173 133 99 52 32 22 13 7 2 0
Capecitabine 548 466 391 308 242 191 155 122 81 42 27 17 12 2 1 0
No. at risk
Eribulin 554 229 88 44 26 17 12 8 8 5 1 0
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Eribulin 385/554 4.1 3.5 to 4.3
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HR, 1.08; 95% CI, 0.93 to 1.25
P = .30
Fig 2. Kaplan-Meier curve for (A) overall survival and (B) progression-free survival (independent review; intent-to-treat population). HR, hazard ratio. One-, 2-, and
3-year survival rates were 64.4% and 58.0% (P  .04), 32.8% and 29.8% (P  .32), and 17.8% and 14.5% (P  .18) for eribulin and capecitabine, respectively.
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16.1% (95% CI, 13.1% to 19.4%) and 19.9% (95% CI, 16.6% to
23.5%; P .10) for eribulin and capecitabine, respectively.
Analyses by stratification factors. Prespecified exploratory analy-
ses were conducted to assess an effect of eribulin according to HER2
status. Although a possible benefit according to HER2 status was
suggested for OS, an interaction test showed no benefit for eribulin
when comparing patients with HER2-negative disease and all other
patients (HER2-positive and unknownHER2 status).
Safety
For eribulin, the median number of treatment cycles was six
(range, one to 65 cycles), and themedian duration of treatmentwas
4.1 months (range, 0.7 to 45.1 months). For capecitabine, the
median number of treatment cycles was five (range, one to 61
cycles), and the median duration of treatment was 3.9 months
(range, 0.7 to 47.4 months). Relative dose-intensity was 87% for
eribulin and 86% for capecitabine.
AEs were reported in 94.1% and 90.5% of patients treated with
eribulin and capecitabine, respectively. Serious AEs were reported in
17.5% of those receiving eribulin and 21.1% of those receiving cape-
citabine; thesewere life-threateningAEs in 2.2%and3.5%of patients,
respectively, and required or prolonged hospitalization in 13.4% and
17.0%ofpatients, respectively.AEs leading todiscontinuation, reduc-
tion, or delay in treatment occurred in 7.9%, 32.0%, and 31.8% of
patients receiving eribulin and in 10.4%, 31.9%, and 35.7% of those
receiving capecitabine, respectively. Fatal AEs (within 30 days of last
dose) occurred in 4.8% of patients receiving eribulin and 6.6% of
patients receiving capecitabine. These were reported as treatment-
related AEs for five patients treated with eribulin (sepsis, pericardial
effusion, sudden death, toxic hepatitis, and renal failure) and four
Table 2. Best Overall Tumor Response As Assessed by Independent and Investigator Review (intent-to-treat population)
Response
Independent Review Investigator Review
Eribulin (n  554) Capecitabine (n  548) Eribulin (n  554) Capecitabine (n  548)
Tumor response
CR
No. of patients 1 0 4 10
% 0.2 0 0.7 1.8
PR
No. of patients 60 63 85 99
% 10.8 11.5 15.3 18.1
Stable disease
No. of patients 313 303 332 278
% 56.5 55.3 59.9 50.7
Progressive disease
No. of patients 125 133 99 126
% 22.6 24.3 17.9 23.0
Not evaluable
No. of patients 11 6 34 35
% 2.0 1.1 6.1 6.4
Unknown
No. of patients 44 43 0 0
% 7.9 7.8 0 0
Unconfirmed CR/PR
No. of patients — — 21 16
% 3.8 2.9
Objective response rate†
No. of patients 61 63 89 109
% 11.0 11.5 16.1 19.9
95% CI 8.5 to 13.9 8.9 to 14.5 13.1 to 19.4 16.6 to 23.5
P‡ .85 .10
Clinical benefit rate§
No. of patients 145 147 182 188
% 26.2 26.8 32.9 34.3
95% CI 22.6 to 30.0 23.2 to 30.7 29.0 to 36.9 30.3 to 38.4
P‡ .84 .61
Duration of response, months
Median 6.5 10.8 6.5 6.7
95% CI 4.9 to 9.0 6.8 to 17.8 4.9 to 7.6 5.8 to 7.9
P .01 .45
Abbreviations: CR, complete response; PR, partial response.
PR/CR was confirmed as per RECIST in no less than 4 weeks, but bone scan was missing at confirmation visit required by a protocol amendment.
†Objective response rate included CR and PR.
‡Fisher’s exact test.
§Clinical benefit rate was an exploratory end point and included CR, PR, or stable disease of at least 6 months in duration.
Unstratified log-rank test.
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patients treated with capecitabine (sepsis, pneumonia, cardiogenic
shock, and pancytopenia).
The most common AEs with eribulin were neutropenia, alope-
cia, leukopenia, global peripheral neuropathy, and nausea. The most
common AEs with capecitabine were hand-foot syndrome, diarrhea,
and nausea (Table 3). Febrile neutropenia occurred at low incidence
with both eribulin (2.0%) and capecitabine (0.9%). Most AEs were
grade 1 or 2. The most common grade 3 or 4 AEs were neutropenia,
leukopenia, asthenia, and global peripheral neuropathy for eribulin,
and hand-foot syndrome, diarrhea, neutropenia, dyspnea, and asthe-
nia for capecitabine. Grade 3 or 4 global peripheral neuropathy oc-
curred in 7.0% of patients receiving eribulin and 0.9% of patients
receiving capecitabine (Table 3). In the eribulin group, the incidences
of grade 3or 4peripheralmotor neuropathy, peripheral sensorimotor
neuropathy, and polyneuropathy were 0.7% (all grade 3), 0.6% (all
grade 3), and 0.6% (0.4% grade 3, 0.2% grade 4), respectively; these
AEs did not occur at grade 3 or 4 in the capecitabine group. Themost
common AEs leading to discontinuation (occurring in  1% of
patients) were neutropenia (1.7%) with eribulin and hand-foot syn-
drome (2.2%) and dyspnea (1.1%) with capecitabine. Colony-
stimulating factorswere receivedby 14.6%and3.6%of patients in the
eribulin and capecitabine arms, respectively.
QoL Analyses
Almost all ( 95%) QoL data were available at baseline for
both arms; completion rates over time decreased similarly in both
arms (Data Supplement). GHS/QoL scores were low at baseline in
both the eribulin and capecitabine arms (mean standard devia-
tion, 56.3 22.2 and 54.7 21.7, respectively). Over time, average
GHS/QoL scores improved in both arms, but the linear mixed
model and pattern-mixture model showed no significant differ-
ence between the groups (linearmixedmodel: estimated treatment
effect,0.068; P .958; pattern-mixture model: estimated treat-
ment effect, 0.082; P .949).
DISCUSSION
Althougheribulin is anactive single agent inpatientswithMBC, itwas
not superior to capecitabine with regard to either OS or PFS. Our
results contrast with those of EMBRACE, in which a statistically sig-
nificant improvement in OS was seen with eribulin compared with
TPC.18 The reasons for this apparent difference are unclear. It is
possible that treatment earlier in the course of MBC is less likely to
impact OS, as a consequence of such patients typically receiving fur-
ther lines of cytotoxic or other therapy. Even if therapeutically more
active, a first- or second-line regimen may not impact on OS when
multiple subsequent lines of effective treatment are administered.
The influence of postprogression therapies on OS is often dis-
cussed in studies ofMBC, particularly when cross over is imbalanced,
and usually in the context of differences in PFS being more apparent
than those inOS (whichdidnot occur inour study). In this trial,more
Table 3. Most Common Adverse Events (incidence of  10% for all grades or  2% for  grade 3 in either arm; safety population)
Adverse Event
Eribulin (n  544) Capecitabine (n  546)
All Grades Grade 3 Grade 4 All Grades Grade 3 Grade 4
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
No. of
Patients %
Hematologic
Neutropenia 295 54.2 134 24.6 115 21.1 87 15.9 23 4.2 4 0.7
Leukopenia 171 31.4 73 13.4 9 1.7 57 10.4 10 1.8 1 0.2
Anemia 104 19.1 11 2.0 0 0 96 17.6 5 0.9 1 0.2
Febrile neutropenia 11 2.0 8 1.5 3 0.6 5 0.9 2 0.4 3 0.5
Nonhematologic
Alopecia 188 34.6 22 4.0
Global peripheral neuropathy 149 27.4 35 6.4 3 0.6 75 13.7 5 0.9 0 0
Nausea 121 22.2 1 0.2 0 0 133 24.4 9 1.6 0 0
Fatigue 91 16.7 11 2.0 0 0 84 15.4 12 2.2 1 0.2
Asthenia 83 15.3 22 4.0 1 0.2 79 14.5 20 3.7 0 0
Diarrhea 78 14.3 6 1.1 0 0 157 28.8 28 5.1 1 0.2
Pyrexia 70 12.9 2 0.4 0 0 31 5.7 3 0.5 0 0
Headache 69 12.7 4 0.7 0 0 57 10.4 2 0.4 1 0.2
Decreased appetite 68 12.5 3 0.6 0 0 81 14.8 9 1.6 0 0
Vomiting 65 11.9 1 0.2 1 0.2 92 16.8 12 2.2 0 0
Dyspnea 56 10.3 10 1.8 2 0.4† 59 10.8 16 2.9 5 0.9‡
Back pain 56 10.3 8 1.5 0 0 43 7.9 3 0.5 0 0
Bone pain 50 9.2 10 1.8 1 0.2 43 7.9 4 0.7 1 0.2
ALT increased 46 8.5 18 3.3 0 0 23 4.2 3 0.5 0 0
Hypokalemia 19 3.5 5 0.9 0 0 25 4.6 9 1.6 2 0.4
Hand-foot syndrome 1 0.2 0 0 0 0 246 45.1 79 14.5 0 0
NOTE. If a patient had  two adverse events in the same system organ class or with the same preferred term with different Common Terminology Criteria for
Adverse Events grades, the event with the highest grade was used for that patient.
Defined as Standardized Medical Dictionary for Regulatory Activities Queries narrow and broad terms.
†Grade 5 events also occurred in four patients (0.7%).
‡Grade 5 events also occurred in three patients (0.5%).
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patientswent on to receive further anticancer treatment after study treat-
ment in the eribulin arm (70.4%) than in the capecitabine arm (62.0%).
Specifically, patients in the eribulin arm could cross over and receive
capecitabine (49.6%), whereas cross over from capecitabine to eribulin
(0.4%)was limitedbyeribulinonlybeingapprovedtoward theendof the
study.Nevertheless, no differences inOSwere seen in this study.
TheOSdata in patientswithHER2-negative diseasewere similar
to those reported in EMBRACE,18 and there was no significant differ-
ence in PFS between treatment groups in the HER2 subgroups.
AlthoughPFSandOSare similar toother studies in this setting,7,8
ORRs in this study are low. This may be explained, at least in part, by
only 88% of patients having disease evaluable for response; the re-
mainderhadnobaseline scanper independent review(1%), abaseline
scanofany typeonly (7%),oraRECISTresponsebutnoconfirmatory
bone scan (3%).
Eribulin had a manageable tolerability profile, consistent with
previous studies; neutropenia, alopecia, leukopenia, and peripheral
neuropathywere themost commonAEs.18,24-27 For patients receiving
eribulin, the incidences of hematologic and grade 3 or 4 AEs were
similar to those in EMBRACE, except for febrile neutropenia. The
total incidence of febrile neutropenia with eribulin was lower in this
trial (2% with eribulin v 0.9% with capecitabine) than in EMBRACE
(5%), in which patients had received more prior lines of chemother-
apy.18 Neutropenia was managed with dose delays, reductions, and
growth factors according to local practice. The use of colony-
stimulating factors was higher in the eribulin group than in the cape-
citabine group (14.6% v 3.6%, respectively), consistent with the
greater incidence of neutropenia. There were, however, no deaths as a
result of neutropenia in either treatment group. AEs experienced with
capecitabine, particularly hand-foot syndrome and diarrhea, were also
consistent with known AEs.10,8,28 Even though this study used the ap-
proved dose of capecitabine (1.25 g/m2 twice per day), these AEs were
generally within the range observed for capecitabine administered at
1.0 g/m2 twice per day,29-35 a dose commonly used in clinical practice.36
Furthermore, dose-intensity was high for both eribulin and capecitabine
in this study.Although incidences of alopecia andperipheral neuropathy
were higher for eribulin comparedwith capecitabine, incidences of diar-
rhea and vomiting were lower. In summary, the AE profiles of both
treatments in this phase III trialwere predictable,manageable, and, over-
all,clinicallyacceptable.Fromthepatients’perspective,averageGHS/QoL
scores generally improved in both treatment arms with no evidence of a
difference between treatments.
In conclusion, this trial didnot demonstrate superiority of eribu-
lin versus capecitabine for eitherOSor PFS. The effects onQoL in this
population of patients with MBC and the AE profiles of eribulin and
capecitabine were consistent with their known AEs.
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■ ■ ■
GLOSSARY TERMS
HER2/neu (human epidermal growth factor recep-
tor 2): also called ErbB2. HER2/neu belongs to the epidermal
growth factor receptor (EGFR) family and is overexpressed in
several solid tumors. Like EGFR, it is a tyrosine kinase receptor
whose activation leads to proliferative signals within the cells. On
activation, the human epidermal growth factor family of recep-
tors are known to form homodimers and heterodimers, each
with a distinct signaling activity. Because HER2 is the preferred
dimerization partner when heterodimers are formed, it is important
for signaling through ligands specific for anymembers of the family. It is
typically overexpressed in several epithelial tumors.
overall survival: the duration between random assignment and
death.
progression-free survival: time from random assignment until
death or first documented relapse, categorized as either locoregional
(primary site or regional nodes) failure or distant metastasis or death.
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